NewcelX AG (NCEL) News & EventsNCELNews & EventsNewcelX AG

US Treasury Yields Rise, Dow Drops Over 700 Points

The sugar high of US Treasury's "put" to stem the rapid rise in longer-dated yields on Wednesday has worn off, sending those maturities higher and indices sharply lower across the board.  Dow Industrials shed over 700 points, S&P 500 and Nasdaq Composite ended the day near their lows, while small-cap Russell 2000 index fell back below 3,000 for the first time in two weeks.  There were few places to hide even in the more defensive areas of the market, with Consumer Staples dragged down by the 9% post-earnings retreat in shares of Walmartand the recently outperforming Healthcare giving back some of those gains.  Tech was also mixed as strength in memory stocks was offset by selling in Infrastructure Software.In the opening hour of the evening session, panic is dialed down - S&P e-minis and Nasdaq 100 contracts are up 0.1%.  In commodities, WTI Crude Oil is still bid above $86 per barrel. while precious metals remain supported by a bout of USD weakness - Gold is above $4,585 and Silver has advanced above $68 per ounce.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Ross Storesup 8.1%ALSO HIGHER -Spotify Technologyup 1.3% after boosting share buybackDOWN AFTER EARNINGS -Flux Powerdown 20.6%Flowers Foodsdown 4.2%OSI Systemsdown 3.7%ALSO LOWER -Aveanna Healthcaredown 9.3% after equity offeringNewcelX Ltd.down 5.0% after selling stock for holders

Selling Stockholders Plan to Sell Up to 694K Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 694K shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

NewcelX Announces Private Placement at $4.033 per Share

NewcelX announced that it has entered into securities purchase agreements for a private placement at a purchase price of $4.033 per share, representing a 20% premium to the last closing price of the company's common shares on July 30. Pursuant to the terms of the securities purchase agreements, the company is selling an aggregate of 347,134 common shares and one series of warrants to purchase an aggregate of 347,134 common shares at an exercise price of $4.437 per share, which is 132% of the last closing price of the company's common shares on July 30, 2026. The offering includes participation from existing shareholders and is expected to close on or about August 14. The company intends to use the net proceeds from the offering, together with its current cash position, and previously announced $25M equity line, primarily to advance NCEL-101, NewcelX's lead program for type 1 diabetes, in collaboration with Eledon Pharmaceuticals, and for working capital and general corporate purposes.